Free to read\ud \ud BACKGROUND AND PURPOSE\ud It has been proposed that BRL37344, SR58611 and CGP12177 activate b3-adrenoceptors in human atrium to increase\ud contractility and L-type Ca2+ current (ICa-L). b3-adrenoceptor agonists are potentially beneficial for the treatment of a variety of\ud diseases but concomitant cardiostimulation would be potentially harmful. It has also been proposed that (-)-CGP12177\ud activates the low affinity binding site of the b1-adrenoceptor in human atrium. We therefore used BRL37344, SR58611 and\ud (-)-CGP12177 with selective b-adrenoceptor subtype antagonists to clarify cardiostimulant b-adrenoceptor subtypes in\ud human atrium.\ud EXPERIMENTAL APPROACH\ud Human right atrium was obtained from patients wit...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Free to read BACKGROUND AND PURPOSE It has been proposed that BRL37344, SR58611 and CGP12177 activat...
The 1AR has two binding sites which can be activated to cause cardiostimulation. The first, termed,...
CA WOS antraštė: beta(3)-adrenergic receptor activation increases human atrial tissue contractility ...
β-Adrenoceptor blocking agents (β-blockers) that at low concentrations antagonize cardiostimulant ef...
β-Adrenoceptor blocking agents (β-blockers) that at low concentrations antagonize cardiostimulant ef...
In atrium and ventricle from failing and non-failing human hearts, activation of beta(1)- or beta(2)...
β-Adrenoceptor blocking agents (β-blockers) that at low concentrations antagonize cardiostimulant ef...
1 We identified putative beta(4)-adrenoceptors by radioligand binding, measured increases in ventric...
Background and Purpose The β-adrenoceptor has at least two binding sites, high and low affinity site...
Two forms of the activated beta(1)-adrenoceptor exist, one that is stabilized by (-)-noradrenaline a...
Objective: To understand the basis of the effectiveness of carvedilol in heart failure by determinin...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Free to read BACKGROUND AND PURPOSE It has been proposed that BRL37344, SR58611 and CGP12177 activat...
The 1AR has two binding sites which can be activated to cause cardiostimulation. The first, termed,...
CA WOS antraštė: beta(3)-adrenergic receptor activation increases human atrial tissue contractility ...
β-Adrenoceptor blocking agents (β-blockers) that at low concentrations antagonize cardiostimulant ef...
β-Adrenoceptor blocking agents (β-blockers) that at low concentrations antagonize cardiostimulant ef...
In atrium and ventricle from failing and non-failing human hearts, activation of beta(1)- or beta(2)...
β-Adrenoceptor blocking agents (β-blockers) that at low concentrations antagonize cardiostimulant ef...
1 We identified putative beta(4)-adrenoceptors by radioligand binding, measured increases in ventric...
Background and Purpose The β-adrenoceptor has at least two binding sites, high and low affinity site...
Two forms of the activated beta(1)-adrenoceptor exist, one that is stabilized by (-)-noradrenaline a...
Objective: To understand the basis of the effectiveness of carvedilol in heart failure by determinin...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...
Objective: Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of rever...